Investor Relations Captor Therapeutics ®
Obtaining positive results from the in vivo study in the CT-02 project
Publication date:
Publication time:
Current report No. 17/2024
Date of preparation: 12.06.2024
Subject: Obtaining positive results from the in vivo study in the CT-02 project
Legal basis: Article 17(1) MAR - confidential information.
The Management Board of Captor Therapeutics S.A. based in Wroclaw ("Company"), informs that has just received data from the completed in vivo study in the EAE model, a well-regarded model of multiple sclerosis. The data shows a dose-dependent effect much stronger than that observed for an NLRP3 inflammasome inhibitor, suggesting that the NEK7 degrader is highly effective in the treatment of the disease. The resulting data are particularly promising because the model tested an interventional approach mimicking real-world treatment scenarios more effectively than preventive methods.